Comparison of Tropisetron with Ondansetron in the Prevention of Cisplatin-induced Nausea and Vomiting.
- Author:
Kyung Shick LEE
1
;
Ji Youn HAN
;
Hanlim MOON
;
Bok Kun LEE
;
Seok Goo CHO
;
Jong Youl JIN
;
Young Sun HONG
;
Hoon Kyo KIM
Author Information
1. Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Korea.
- Publication Type:Multicenter Study ; Original Article ; Randomized Controlled Trial
- Keywords:
Nausea;
Vomiting;
Cisplatin;
Tropisetron;
Ondnasetron
- MeSH:
Antiemetics;
Biological Availability;
Cisplatin;
Constipation;
Cross-Over Studies;
Dexamethasone;
Drug Therapy;
Half-Life;
Headache;
Humans;
Nausea*;
Ondansetron*;
Plasma;
Receptors, Serotonin, 5-HT3;
Vomiting*
- From:Journal of the Korean Cancer Association
1997;29(2):332-339
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Tropisetron (Nabovan (R)) is a new specific 5-HT3 receptor antagonist with a long terminal half life in plasma and high bioavailability after oral intake. We compared the antiemetic effectiveness and tolerability of tropisetron with ondansetron in the highly emetogenic chemotherapy (including cisplatin > or =50 mg/m2). MATERIALS AND METHODS: Thirty-nine patients were administered in a randomized, multicenter, open, cross-over study and received either tropisetron plus dexamethasone (n=31) or ondansetron plus dexamethasone (n=34) during six days of two successive cycles of chemotherapy. RESULTS: Total control of vomiting with either Ondansetron or tropisetron was 94.2 % vs 93.5 % in D1 (P=0.157); 90.6 % vs 93.1 % in D2 (P=0.18); 90.3 % vs 93.1 % in D3 (P=0.655); 96.4% vs 96.4 % in D4 (P=0.157); 96.4 % vs 100 % in D5 (P=0.317); 96.4 % vs 100% in D6, respectively. The duration of nausea showed significant decreasements in tropisetron at D5 and D6 (P=0.025, P=0.03, respectively), but the severity of nausea and performance status showed no significance. Headache and constipation were the most common side effects in both groups. CONCLUSION: There was no significant difference in efficacy and tolerability between tropisetron and ondansetron in the cisplatin-based chemotherapy.
